What’s the current market cap for Covista stock?

Covista (CVSA) has a market cap of $4.2B as of June 02, 2026.

What is the P/E ratio for Covista stock?

The price to earnings (P/E) ratio for Covista (CVSA) stock is 18.99 as of June 02, 2026.

Does Covista stock pay dividends?

No, Covista (CVSA) stock does not pay dividends to its shareholders as of June 02, 2026.

When is the next Covista dividend payment date?

Covista (CVSA) stock does not pay dividends to its shareholders.

What is the beta indicator for Covista?

Covista (CVSA) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Covista stock | $CVSA Share Price

13:30

15:10

16:45

18:25

20:00

About Covista

Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.

Ticker

$CVSA

Sector

Consumer Discretionary

Primary listing

NYSE

Employees

4,727

Headquarters

Chicago, United States

Website

www.covista.com

Covista Metrics

BasicAdvanced

$4.2bn

18.99

$6.43

0.63

What the Analysts think about Covista

Analyst ratings (Buy, Hold, Sell) for Covista stock.

Bulls say / Bears say

Covista raised its fiscal year 2026 revenue outlook to $1.93 billion–$1.945 billion and its adjusted EPS guidance to $7.95–$8.15, showing management’s confidence in ongoing growth. (Business Wire)

Walden University’s enrollment climbed 12.3% year-over-year in Q3 FY 2026, reaching its highest total enrollment on record and highlighting strong student demand. (Business Wire)

American University of the Caribbean and Ross University School of Medicine reached a combined 97% first-time residency attainment rate for the 2025–2026 graduating class, marking five consecutive years above 95%. (Business Wire)

Diluted earnings per share dropped 24.5% to $1.20 in Q3 FY 2026, as net income fell to $41.6 million from $60.8 million a year ago. (SEC 10-Q)

Total student enrollment in the medical and veterinary segment increased only 4.1% year-over-year in Q3 FY 2026, trailing the company’s overall enrollment growth of 6.8%. (Business Wire)

Dependence on federal and state financial aid programs exposes Covista to regulatory risk; any changes reducing student eligibility or funding could significantly impact its financial condition. (SEC 10-Q)

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

Covista Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Covista Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CVSA

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Walden University’s enrollment climbed 12.3% year-over-year in Q3 FY 2026, reaching its highest total enrollment on record and highlighting strong student demand. (Business Wire)

Diluted earnings per share dropped 24.5% to $1.20 in Q3 FY 2026, as net income fell to $41.6 million from $60.8 million a year ago. (SEC 10-Q)

Total student enrollment in the medical and veterinary segment increased only 4.1% year-over-year in Q3 FY 2026, trailing the company’s overall enrollment growth of 6.8%. (Business Wire)

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.